Business Context and Reporting Period
Company: PainReform Ltd. (PRFX)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: PainReform is a specialty pharmaceutical company developing PRF-110, an extended-release drug-delivery system for post-surgical pain relief. In March 2025 (subsequent to the reporting period), the company acquired DeepSolar, an AI-driven solar analytics technology, diversifying into the renewable energy software sector.
Key Financial Metrics
| Metric (USD in thousands) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(14,588) | $(9,344) | $(8,792) |
| Operating Loss | $(14,673) | $(9,584) | $(8,869) |
| Research & Development Expenses | $(11,705) | $(6,035) | $(4,422) |
| General & Administrative Expenses | $(2,968) | $(3,549) | $(4,447) |
| Cash and Cash Equivalents (End of Period) | $4,271 | $8,036 | $4,106 |
| Accumulated Deficit | $(56,451) | $(41,863) | $(32,519) |
| Net Cash Used in Operating Activities | $(12,621) | $(6,679) | $(6,459) |
| Net Cash Provided by Financing Activities | $8,863 | $4,616 | $0 |
Note: The company has never generated revenue. All financial figures are in U.S. dollars.
Material Changes vs. Prior Period
- Increased R&D Spend: Research and development expenses increased by 95% (from $6.0 million in 2023 to $11.7 million in 2024), primarily driven by a $6.0 million increase in clinical trial and manufacturing costs for the PRF-110 Phase 3 trial.
- Worsened Net Loss: Net loss increased by 57% year-over-year to $14.6 million, reflecting the surge in clinical trial expenditures.
- Cash Position Decline: Cash and cash equivalents decreased by approximately 47% from $8.0 million in 2023 to $4.3 million in 2024 due to high operating burn rates.
- Share Structure: The company executed two reverse share splits in 2024 (1-for-6 and 1-for-4), resulting in a cumulative 1-for-24 split. Outstanding shares as of December 31, 2024, were 1,471,412.
Guidance, Outlook, Risks, and Unusual Items
Clinical Trial Setback (PRF-110)
In December 2024, the company announced that its Phase 3 clinical trial for PRF-110 (post-surgical pain) did not meet its primary endpoint. While the drug showed statistically significant superiority over placebo for the first 48 hours, data for the final 24-hour period (required for the 72-hour primary endpoint) was incoherent and could not be clarified. The company is conducting further R&D to refine pharmacokinetics and pharmacodynamics.
Going Concern Warning
The independent auditor has included an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern. With only $4.3 million in cash and a projected operating burn rate, the company may not meet financial obligations for the next 12 months without additional capital.
DeepSolar Acquisition (Subsequent Event)
On March 5, 2025, the company closed an acquisition of DeepSolar (AI solar analytics) from BladeRanger Ltd. Consideration included shares and warrants. This marks a strategic pivot to a new revenue-generating business line, though it introduces integration risks and requires additional capital.
Internal Control Weakness
Management identified a material weakness in internal control over financial reporting due to insufficient finance staff and incomplete segregation of duties. Remediation plans include hiring additional personnel.
Geopolitical Risks
Operations are based in Israel. The ongoing conflict with Hamas and regional instability pose risks to personnel availability (reserve duty), supply chains, and capital market access.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $4.3 million cash balance against the projected burn rate required to fund the re-design of PRF-110 trials and the integration of DeepSolar.
- Capital Raising Plans: Confirm the status of the At-The-Market (ATM) offering program and any pending private placements to address the going concern warning.
- PRF-110 Path Forward: Assess the timeline and cost estimates for the new R&D activities required to resolve the Phase 3 data incoherence.
- DeepSolar Integration: Evaluate the revenue potential and immediate cash flow impact of the DeepSolar acquisition, noting it is in early commercialization stages.
- Internal Controls: Monitor progress on hiring finance staff to remediate the material weakness in internal controls.
- Nasdaq Compliance: Verify the company's status regarding Nasdaq minimum bid price and minimum equity requirements (the company received an exception for the equity rule through April 14, 2025).